Hadasit Bio-Holdings

Venture Capital Active Jerusalem, Israel Est. 2005
Visit website ↗ LinkedIn
Last updated 2026-06-18
Portfolio
5
in our dataset
Rounds participated
13
Rounds led
0
Rounds' value
$106.5M
total disclosed, rounds participated
Stages
Seed, A Round

About

Hadasit Bio-Holdings (HBL) is a publicly traded subsidiary of Hadasit Ltd, the technology transfer company of the Hadassah University Hospital in Jerusalem. It was founded and floated on the Tel Aviv Stock Exchange and recently on the OTC (OTCBB) in order to allow public participation in the highly promising field of biotechnology. HBL focuses on funding its portfolio companies execution of phase 1 and preparation for phase 2. Success in either of these stages can multiply the valuation of each company up to 10 times for each milestone. HBL enables public investment in companies based on intellectual property generated by the Hadassah University Hospital, which is responsible for the majority of Israels hospital-based translational research. In addition to public holdings (35%), including major Israeli institutional investors, HBL is held by Hadasit (23%), Centures Investments (27%), and LifeMapSciences (15%). The traded stock provides investment exposure to a select cluster of six biotechnology companies based on inventions developed and owned by Hadassah University.

Portfolio · 5

KAHR Medical
Fusion Proteins for Treating Cancer and Autoimmune Diseases
5 rounds $75.5M committed Latest: 2021-06
Enlivex Therapeutics
Macrophage Reprogramming Cell Therapies for Life-threatening Diseases
2 rounds $15.0M committed Latest: 2017-09
BioMarCare
Tumor Biomarker Technologies for Early Cancer Diagnosis
2 rounds $900K committed Latest: 2011-08
CellCure Neurosciences
Cell Therapies for Neural Degenerative Diseases
2 rounds $8.1M committed Latest: 2010-10
ProtAb
Antibody for Treating Autoimmune Disorders
2 rounds $7.0M committed Latest: 2010-04

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences4
Undisclosed1

Q&A

What is Hadasit Bio-Holdings' primary investment focus?
Hadasit Bio-Holdings focuses on funding its portfolio companies' execution of Phase 1 and preparation for Phase 2 clinical trials in biotechnology. The firm invests in companies based on intellectual property generated by the Hadassah University Hospital.
What is Hadasit Bio-Holdings' most notable exit?
Hadasit Bio-Holdings had a notable exit in March 2019 with Enlivex Therapeutics, which completed a reverse merger and was listed on NASDAQ.
Which investment stages does Hadasit Bio-Holdings typically target?
Hadasit Bio-Holdings typically targets Seed and A Round investment stages.
Can you name some of Hadasit Bio-Holdings' portfolio companies?
Hadasit Bio-Holdings' portfolio includes companies like CellCure Neurosciences, which focuses on cell therapies for neural degenerative diseases.
What is the sector concentration of Hadasit Bio-Holdings' investments?
Hadasit Bio-Holdings shows a strong concentration in the Health Tech & Life Sciences sector, with 10 investment rounds in this area.
Who are the key executives at Hadasit Bio-Holdings?
Dr. Tamar Raz serves as the CEO, and Liat Hadad Simhayoff is the CFO at Hadasit Bio-Holdings.
When was Hadasit Bio-Holdings founded?
Hadasit Bio-Holdings was founded in 2005.
What is the ownership structure of Hadasit Bio-Holdings?
Hadasit Bio-Holdings is publicly traded with 35% public holdings, 23% held by Hadasit, 27% by Centures Investments, and 15% by LifeMapSciences.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)